Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma

NCT03928275 is registered in ClinicalTrials.gov with Carman Giacomantonio as lead sponsor.

NCT NCT03928275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03928275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma
Lead sponsor
Carman Giacomantonio
Phase
Phase 2/3
Overall status
Withdrawn
Start date
December 1, 2021
Completion date
September 1, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous metastatic melanoma